Changes of Cell Adhesion Molecules and T Cell Subset Populations in Acute Myeloid Leukemia Patients Undergoing Intravenous Administration of Cytarabine Supplemented with Idarubicin

Table 3

The proportions of CD4⁺IL-10 Tregs and CD4⁺CD25⁺CD127⁻Foxp3⁺ Tregs in peripheral blood in AML patients following intravenous administration of cytarabine supplemented with either idarubicin or daunorubicin.

Group	Case	Time	CD4^+IL-10 Tregs (%)	CD4^+CD25^+CD127^−Foxp3^+ Tregs (%)
Control group	44	Pretreatment	27.75 ± 3.97	23.31 ± 3.87
		Posttreatment	23.47 ± 2.53	19.89 ± 1.75
t			6.031	5.341
			<0.001	<0.001
Study group	44	Pretreatment	28.11 ± 3.63	23.07 ± 3.93
		Posttreatment	20.40 ± 2.04^a	18.28 ± 1.43^a
t			12.280	7.597
			<0.001	<0.001